



# Fourth-Quarter and Full-Year 2023 Earnings Results

FEBRUARY 27, 2024



# Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures

Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This presentation contains forward-looking statements that reflect management’s expectations about future events and the Company’s operating plans and performance and speak only as of the date hereof. You can identify these forward-looking statements by the use of forward-looking words such as “will,” “may,” “plan,” “estimate,” “project,” “believe,” “anticipate,” “expect,” “intend,” “should,” “would,” “could,” “target,” “goal,” “continue to,” “positioned to,” “are confident” or the negative versions of those words or other comparable words. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, are forward-looking statements. Any forward-looking statements contained in this release are based upon our historical performance and on our current plans, estimates and expectations of the Company’s future performance and the future performance of the markets in which the Company operates in light of information currently available to us. The inclusion of this forward-looking information should not be regarded as a representation by us that the future plans, estimates or expectations contemplated by us will be achieved. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, without limitation, any disruption in the availability or supply of, or increases in the price of, ethylene oxide (“EO”) or Cobalt-60 (“Co-60”), or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions arising from the United States, Canadian, United Kingdom or European Union relations with Russia; fluctuations in foreign currency exchange rates; changes in industry trends, environmental, health and safety regulations or preferences, and general economic, social and business conditions; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to use of EO and/or emission and releases of EO from our facilities in Illinois, Georgia and New Mexico and the possibility that other claims will be made in the future relating to these or other facilities; our ability to increase capacity at existing facilities, renew leases for our leased facilities; our ability to attract and retain qualified employees; the risks of doing business internationally, including global and regional economic and political instability and compliance with numerous laws and regulations in multiple jurisdictions; and an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully. For additional discussion of these risks and uncertainties, please refer to the Company’s filings with the SEC, such as its annual and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as otherwise required by law.

This presentation includes Adjusted EBITDA, Adjusted EBITDA margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Segment Income Margin, Adjusted EPS, Net Debt and Net Leverage Ratio, which are unaudited financial measures that are not based on any standardized methodology prescribed by GAAP. Adjusted EBITDA, Adjusted EBITDA margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Segment Income Margin, Adjusted EPS, Net Debt and Net Leverage Ratio may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Adjusted EBITDA, Adjusted EBITDA margin, Tax Rate Applicable to Adjusted Net Income, Adjusted Net Income, Segment Income Margin, Adjusted EPS, Net Debt and Net Leverage Ratio should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. See the Appendix for a reconciliation of net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA and Adjusted EPS and a reconciliation of total debt, the most directly comparable financial measure calculated and presented in accordance with GAAP, to Net Debt and Net Leverage.

This presentation refers to, and in other communications with investors the Company may refer to, net sales or revenues or other historical financial information on a “constant currency” basis, which is a non-GAAP financial measure defined in the Appendix to this presentation.

We use these non-GAAP financial measures as the principal measures of our operating performance. Management believes these measures allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained without these measures and their disclosure. In addition, we believe these measures will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses these measurements in their financial analysis and operational decision-making and Adjusted EBITDA serves as the key metric for attainment of our primary annual incentive program. These measures may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

The Company does not provide a reconciliation for non-GAAP financial measures on a forward-looking basis where it is unable to provide a meaningful or accurate calculation or estimation of reconciling items without unreasonable effort. The Company cannot reconcile its expected Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Net Leverage Ratio without unreasonable effort because certain items that impact net income, earnings per share and other reconciling metrics are out of the Company’s control and/or cannot be reasonably predicted at this time, including uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company’s industry and estimated total and serviceable addressable markets. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We have not independently verified this market data. While we are not aware of any misstatements regarding any industry or similar data presented herein, such data involve risks and uncertainties and are subject to change based on various factors, including those described under the headings of “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Form 10-K, and in the Company’s other SEC filings. In addition, projections, assumptions and estimates of the Company’s future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.

The Sotera Health name, our logo and other trademarks mentioned in this presentation are the property of their respective owners. All Company data and financial information included in this presentation is as of December 31, 2023, unless otherwise stated.





**Michael B. Petras, Jr.**  
*Chairman and Chief Executive Officer*



**Jonathan M. Lyons**  
*Senior Vice President and Chief Financial Officer*

# Safeguarding Global Health® Through Our Sterilization Services, Lab Testing and Advisory Services

## What we do...

Leader in sterilization services



Leader in lab testing and advisory services



## ...and how we do it...

- Provide mission-critical services to **blue chip customers with multi-year contracts**
- Unmatched **network of local facilities** to support customer requirements and growth
- In an increasingly regulated industry, we are a **global leader in technical and regulatory expertise**
- **Organic and inorganic growth**
- Our culture – **safety, quality, accountability and excellence**

## ...leads to strong results


- **Annual revenue growth every year** since 2005
- **2023 Adjusted EBITDA margins<sup>(1)</sup> greater than 50%**
- **~\$33 billion TAM<sup>(2)</sup>** and growing
- Consistent track record of **cash flow generation**
- **Well positioned for growth in global healthcare market** without payor reimbursement risk

***Our capabilities, scale and know-how are not easily replicated...  
Our customers depend on our mission-critical services in any economic environment***

(1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.

(2) 2019 Management estimated total addressable markets for in-house and outsourced terminal sterilization and outsourced medical device and pharmaceutical lab testing.

# Our Customers Trust and Value Our Expertise



**Global scale with integrated facility network**

**Expertise and strong track record in highly regulated markets**

**Ability to meet customers' regulatory needs**

**Comprehensive end-to-end services offered**

**Provide customer peace-of-mind**

**Experienced management team with established track record**

<sup>(1)</sup> Based on revenue for the year ended December 31, 2023.

# Safeguarding Global Health®

- Our mission is at the heart of our work
- Click [here](#) to view how our global teams help to reduce the prevalence of hospital acquired infections, benefiting both patients and hospitals
- Our end-to-end services, in addition to our industry-leading expertise in science, safety and quality, allow us to deliver on Safeguarding Global Health®



# Q4 2023 Highlights

## Business & Market Update

- Nordion successfully delivered 50% of FY 2023 revenue in Q4
- Sterigenics and Nelson Labs continued to experience volume softness
- Challenging macro-economic backdrop, including interest rate, inflation and customer supply-chain pressures

## Financial Performance

- Top- and bottom-line growth
- Strong Adjusted EBITDA margin<sup>(1)</sup> performance of 53.7%
- Sequential quarterly revenue and Adjusted EBITDA growth for all three businesses

## Capital Deployment and Liquidity

- 3 active Sterigenics expansions and Nordion Cobalt-60 development programs progress
- Net Leverage Ratio<sup>(1)</sup> finished at 3.8x, within target range of 2.0x – 4.0x
- Strong liquidity of approximately \$700M; no outstanding borrowings on the revolver

(1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.



## 2023 Full-Year Highlights

- ✓ Another year of top- and bottom-line growth and 50%+ Adjusted EBITDA<sup>(1)</sup> margins
- ✓ Nordion delivered significant Q4 volume
- ✓ Double-digit growth in advisory services at Nelson Labs
- ✓ Four Sterigenics capacity expansions completed
- ✓ Continued progress in Sterigenics industry-leading EO facility enhancements
- ✓ Completed settlement of 880 claims in connection with the Illinois EO litigation
- ✓ Reached settlement of approximately 25% of Georgia EO personal injury claims
- ✓ Strengthened liquidity position by over \$200M
- ✓ Net Leverage Ratio<sup>(1)</sup> to 3.8x within our long-term target range of 2.0x – 4.0x
- ✓ Published 2023 Corporate Responsibility report

<sup>(1)</sup> This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.



# Corporate Responsibility is Integral to Sotera Health

- Focus follows naturally from our Mission and Values
  - Committed to **Safeguarding Global Health**<sup>®</sup>
  - We help to ensure the safety of millions of patients and health care workers globally
  - Our work aligns with the UN Sustainable Development Goal 3 – to ensure healthy lives and promote well-being for all people around the world
- Strong Governance is fundamental
  - Oversight by Nominating & Corporate Governance Committee and full Board
  - Outreach to shareholders representing over 60% of outstanding shares not held by affiliates
  - Karen A. Flynn joined Board as new independent director
- Internal ESG Committee with Executive Management Leadership
  - Regular reviews with CEO
  - Multi-year strategy to coordinate, drive and disclose activities and new initiatives most meaningful to stakeholders
  - Published 2023 Corporate Responsibility Report and issued new Human Rights Policy





# FINANCIAL OVERVIEW





# Full Year 2023 Consolidated Financial Performance

\$ In millions, except Adjusted EPS and Adjusted EBITDA margin



## Revenue



## Adjusted EBITDA <sup>(1)</sup>



## Adjusted EPS <sup>(1)</sup>





(1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.

(2) Adjusted EBITDA margin is equal to Adjusted EBITDA divided by net revenues. Please refer to Non-GAAP Financial Measures provided in the Appendix.

# Sterigenics 2023 Financial Performance

\$ In millions





- Revenue growth for the quarter was driven by favorable pricing and changes in foreign currency rates, partially offset by unfavorable volume and mix
- Segment income growth for the quarter was also driven by favorable pricing and changes in foreign currency rates, partially offset by higher costs and unfavorable volume and mix

(1) Segment income is defined to exclude, among other things, depreciation and amortization. Please refer to our consolidated financial statements for more information.

(2) Segment income margin is equal to segment income divided by net revenues. Please refer to Non-GAAP Financial Measures provided in the Appendix.

# Nordion 2023 Financial Performance

\$ In millions





- Revenue, segment income and segment income margin increases for the quarter were driven by favorable impacts from volume and mix, as well as pricing as Nordion generated approximately 50% of its full-year revenues in the quarter, as expected

(1) Segment income is defined to exclude, among other things, depreciation and amortization. Please refer to our consolidated financial statements for more information.

(2) Segment income margin is equal to segment income divided by net revenues. Please refer to Non-GAAP Financial Measures provided in the Appendix.

# Nelson Labs 2023 Financial Performance

\$ In millions



- Revenue growth for the quarter was driven by favorable pricing and changes in foreign currency exchange rates, partially offset by unfavorable volume and mix
- Segment income and segment income margin declines for the quarter were driven by unfavorable volume and mix coupled with the impact of inflation, partially offset by favorable pricing


(1) Segment income is defined to exclude, among other things, depreciation and amortization. Please refer to our consolidated financial statements for more information.

(2) Segment income margin is equal to segment income divided by net revenues. Please refer to Non-GAAP Financial Measures provided in the Appendix.

# Net Leverage, Liquidity and Investments

\$ In millions


## Liquidity



### Liquidity Position

- Continued strong liquidity position of approximately \$700M as of Q4 2023
- No borrowings on Revolving Line of Credit as of Q4 2023


## Net Leverage<sup>(1)</sup>



### Long-range target of 2.0x – 4.0x

- Net Leverage Ratio<sup>(1)</sup> was temporarily above target range beginning in Q2 due to \$500M Term Loan and subsequent \$408M settlement payout
- Net leverage Ratio<sup>(1)</sup> reduction of 0.4x from Q2 to Q4, finishing at 3.8x

## Capital Expenditures<sup>(2)</sup>



### Investing to Meet Customer Demand

- **Sterigenics:** 3 active capacity expansions; continued EO facility investments
- **Nordion:** Cobalt-60 development projects
- **Nelson Labs:** Pharma expansion & lab information management system

(1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.  
 (2) Excludes any Capital Expenditures included in accounts payable or accruals at the end of the applicable period.  
 (3) \$408M associated with Illinois EO Settlement from cash and cash equivalents, which was released from escrow on June 30, 2023.  
 (4) Revolving availability is calculated as maximum facility size less letters of credit.  
 (5) Maximum facility size was \$347.5M as of December 31, 2022 and increased to \$423.8M in March 2023.



---

# 2024 Outlook

*On the following slides, Sotera Health presents an overview of its full-year 2024 outlook, including certain non-GAAP financial measures. As outlined in the Company's February 27, 2024 press release, Sotera Health does not provide a reconciliation of the forward-looking Adjusted EBITDA, Adjusted Net Income, Adjusted EPS and Net Leverage Ratio outlook to the most directly comparable GAAP measure, as this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, including, among others, uncertainties caused by changes to the regulatory landscape, restructuring items and certain fair value measurements, all of which are potential adjustments for future earnings. The variability of these items could have a potentially unpredictable, and a potentially significant, impact on our future GAAP results.*

# Full-year 2024 Outlook<sup>(1)</sup>

	FY 2024 Outlook
Net Revenues	+4.0% to +6.0%
Adj EBITDA <sup>(2)</sup>	+4.0% to +6.0%
Interest Expense	\$170M to \$180M
Adj NI Tax Rate <sup>(2)</sup>	31.5% to 34.5%
Adj EPS <sup>(2)</sup>	\$0.67 to \$0.75
Weighted Avg. Diluted Shares	283M to 285M
Capital Expenditures	\$205M to \$225M

(1) The outlook provided above contains a number of assumptions, including, among others, the Company's current expectations regarding supply chain continuity, particularly for the supply of EO and Co-60, the impact of inflationary trends, including their impact on energy prices and the supply of labor and the expectation that exchange rates as of January 31, 2024 remain constant for the remainder of 2024. Our outlook is based on current plans and expectations and is subject to several known and unknown risks and uncertainties, including those set forth above in "Cautionary Note Regarding Forward-Looking Statements."

(2) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.

# Other 2024 Guidance Items

## General Commentary

- 2024 Guidance assumes no M&A activity
- Guidance assumes January 31, 2024 foreign exchange rates remain constant in 2024
- Interest expense change in presentation (see slide 18)

## Cadence

- Q1 typically the softest quarter of the year
- Nordion and Nelson Labs revenue 1H lower than 2H; Q1 the lightest quarter
- Sterigenics volume recovery assumed during 2H of 2024

## Capital Deployment & Net Leverage

- Capital deployment priorities continue to be organic growth, leverage reduction and opportunistic M&A
- Expect to reduce Net Leverage

(1) The outlook provided above contains a number of assumptions, including, among others, the Company's current expectations regarding supply chain continuity, particularly for the supply of EO and Co-60, the impact of inflationary trends, including their impact on energy prices and the supply of labor and the expectation that exchange rates as of January 31, 2024 remain constant for the remainder of 2024. Our outlook is based on current plans and expectations and is subject to several known and unknown risks and uncertainties, including those set forth above in "Cautionary Note Regarding Forward-Looking Statements."

# Interest Expense Presentation

- In Q2 2023, the Company closed on a new \$500M term loan to fund the \$408M Illinois EO settlement
- Consistent with the Company's treatment of EO litigation-related costs, beginning at loan inception the Company excluded the tax-effected interest expense associated with \$408M of the new \$500M term loan to calculate Adjusted Net Income (ANI)<sup>(1)</sup>
- Beginning in 2024, the Company is changing the approach and will no longer make this adjustment
- The following table displays the comparable figures for 2023 reflecting this change

	Year Ended December 31, 2023			
	FY 2023 As Reported	Term Loan Interest Adjustment	Tax Adjustment <sup>(2)</sup>	FY 2023 Update <sup>(2)</sup>
<i>\$ in millions</i>				
Adjusted net income (ANI) <sup>(1)</sup>	\$ 230.1	\$ (26.8)	\$ 1.0	\$ 204.3
Weighted average common shares outstanding - diluted	283.2	-	-	283.2
Effective tax rate	31.4%		2.4%	33.8%
Adjusted earnings per share <sup>(1)</sup>	\$ 0.81	\$ (0.09)	\$ -	\$ 0.72

(1) This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.

(2) The tax adjustment and resulting FY 2023 update in this presentation table reflects a correction to the figures originally published on February 27, 2024.

# Appendix

# Non-GAAP Financial Measures

(unaudited)

(dollars in thousands, except per share amounts)

	Three Months Ended December 31,		Year Ended December 31,	
	2023	2022	2023	2022
<b>Net income (loss)</b>	<b>\$ 38,681</b>	<b>\$ (319,719)</b>	<b>\$ 51,376</b>	<b>\$ (233,570)</b>
Amortization of intangible assets	20,058	19,958	81,348	81,554
Share-based compensation <sup>(a)</sup>	8,229	6,256	32,364	21,211
Gain (loss) on foreign currency and derivatives not designated as hedging instruments, net <sup>(b)</sup>	(3,011)	7,938	(1,552)	3,150
Acquisition and divestiture related charges, net <sup>(c)</sup>	120	420	937	1,398
Business optimization project expenses <sup>(d)</sup>	217	617	7,310	2,226
Plant closure expenses <sup>(e)</sup>	55	954	(585)	4,730
Impairment on investment in unconsolidated affiliate <sup>(f)</sup>	—	—	—	9,613
Professional services and other expenses relating to EO sterilization facilities <sup>(g)</sup>	20,222	22,401	72,122	72,639
Georgia EO litigation settlement <sup>(h)</sup>	—	—	35,000	—
Illinois EO litigation settlement <sup>(i)</sup>	—	408,000	—	408,000
Accretion of asset retirement obligations <sup>(j)</sup>	731	550	2,413	2,194
COVID-19 expenses <sup>(k)</sup>	—	1	—	155
Income tax benefit associated with pre-tax adjustments <sup>(l)</sup>	(11,166)	(77,744)	(50,617)	(103,081)
<b>Adjusted Net Income</b>	<b>74,136</b>	<b>69,632</b>	<b>230,116</b>	<b>270,219</b>
Interest expense, net <sup>(m)</sup>	33,793	24,516	116,068	78,490
Depreciation <sup>(n)</sup>	20,664	16,504	76,577	64,000
Income tax provision applicable to Adjusted Net Income <sup>(o)</sup>	38,155	18,961	105,268	93,540
<b>Adjusted EBITDA<sup>(p)</sup></b>	<b>\$ 166,748</b>	<b>\$ 129,613</b>	<b>\$ 528,029</b>	<b>\$ 506,249</b>
<b>Net Revenues</b>	<b>\$ 310,239</b>	<b>\$ 251,590</b>	<b>\$ 1,049,288</b>	<b>\$ 1,003,687</b>
<b>Adjusted EBITDA Margin</b>	<b>53.7 %</b>	<b>51.5 %</b>	<b>50.3 %</b>	<b>50.4 %</b>
<b>Weighted average number of shares outstanding</b>				
Basic	281,335	280,417	281,008	280,096
Diluted	283,339	280,417	283,222	280,096
<b>Earnings (loss) per share</b>				
Basic	\$ 0.14	\$ (1.14)	\$ 0.18	\$ (0.83)
Diluted	0.14	(1.14)	0.18	(0.83)
<b>Adjusted earnings per share</b>				
Basic	\$ 0.26	\$ 0.25	\$ 0.82	\$ 0.96
Diluted	0.26	0.25	0.81	0.96

## Non-GAAP Financial Measures (continued)

- (a) Represents share-based compensation expense to employees and non-employee directors.
- (b) Represents the effects of (i) fluctuations in foreign currency exchange rates, (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion, and (iii) unrealized gains and losses on interest rate derivatives not designated as hedging instruments.
- (c) Represents (i) certain direct and incremental costs related to the acquisitions of RCA and BioSciences Labs and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.
- (d) Represents professional fees, exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integration of recent acquisitions, operating structure realignment and other process enhancement projects.
- (e) Represents professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility. The twelve months ended December 31, 2023 also includes a \$1.0 million cancellation fee received from a tenant in connection with the termination of an office space lease at the Nordion facility.
- (f) Represents an impairment charge on an equity method investment in a joint venture.
- (g) Represents litigation and other professional fees associated with our EO sterilization facilities. This includes \$8.8 million and \$26.8 million, respectively, of interest expense, net for the three and twelve months ended December 31, 2023 associated with Term Loan B that was issued to finance the \$408.0 million settlement of 880 pending and threatened EO claims against the Defendant Subsidiaries in Illinois under Settlement Agreements entered into on March 28, 2023.
- (h) Represents the cost to settle 79 pending EO claims against the Defendant Subsidiaries in Georgia under a Settlement Term Sheet entered into on December 21, 2023.
- (i) Represents the cost to settle 880 pending and threatened EO claims against the Defendant Subsidiaries in Illinois pursuant to Settlement Agreements entered into on March 28, 2023.
- (j) Represents non-cash accretion of asset retirement obligations related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
- (k) Represents non-recurring costs associated with the COVID-19 pandemic, including incremental costs to implement workplace health and safety measures.
- (l) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities, and unusual items from our presentation of adjusted net income.
- (m) The three and twelve months ended December 31, 2023 excludes \$8.8 million and \$26.8 million, respectively, of interest expense, net on Term Loan B attributable to the loan proceeds that were used to fund the \$408.0 million Illinois EO litigation settlement. The three and twelve months ended December 31, 2022 exclude a \$7.8 million and \$1.7 million net decrease, respectively, in the fair value of interest rate derivatives not designated as hedging instruments recorded to interest expense.
- (n) Includes depreciation of Co-60 held at gamma irradiation sites.
- (o) Represents the difference between the income tax provision/benefit as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (l).
- (p) \$24.4 million and \$20.9 million of the adjustments for the three months ended December 31, 2023 and 2022, respectively, and \$94.1 million and \$83.6 million of the adjustments for the year ended December 31, 2023 and 2022, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.



# Non-GAAP Financial Measures (continued)

(unaudited)  
(dollars in thousands)

	Twelve Months Ended		
	September 30, 2023	June 30, 2023	March 31, 2023
<b>Net loss</b>	<b>\$ (307,024)</b>	<b>\$ (268,274)</b>	<b>\$ (261,369)</b>
Amortization of intangible assets	81,248	81,286	81,979
Share-based compensation <sup>(a)</sup>	30,391	26,629	24,021
Loss on foreign currency and derivatives not designated as hedging instruments, net <sup>(b)</sup>	9,397	11,258	10,237
Acquisition and divestiture related charges, net <sup>(c)</sup>	1,237	1,612	2,150
Business optimization project expenses <sup>(d)</sup>	7,710	7,508	4,656
Plant closure expenses <sup>(e)</sup>	314	2,815	3,164
Impairment of investment in unconsolidated affiliate <sup>(f)</sup>	—	—	9,613
Professional services and other expenses relating to EO sterilization facilities <sup>(g)</sup>	74,301	70,284	70,882
Illinois EO litigation settlement <sup>(h)</sup>	408,000	408,000	408,000
Georgia EO litigation settlement <sup>(i)</sup>	35,000	—	—
Accretion of asset retirement obligations <sup>(j)</sup>	2,232	2,203	2,246
COVID-19 expenses <sup>(k)</sup>	1	7	52
Income tax benefit associated with pre-tax adjustments <sup>(l)</sup>	(117,195)	(111,848)	(107,621)
<b>Adjusted Net Income</b>	<b>225,612</b>	<b>231,480</b>	<b>248,010</b>
Interest expense, net <sup>(m)</sup>	106,791	96,407	88,280
Depreciation <sup>(n)</sup>	72,417	70,308	67,064
Income tax provision applicable to Adjusted Net Income <sup>(o)</sup>	86,074	83,523	86,014
<b>Adjusted EBITDA<sup>(p)</sup></b>	<b>\$ 490,894</b>	<b>\$ 481,718</b>	<b>\$ 489,368</b>
<b>Net Revenues</b>	<b>\$ 990,639</b>	<b>\$ 976,166</b>	<b>\$ 987,523</b>
<b>Adjusted EBITDA Margin</b>	<b>49.6 %</b>	<b>49.3 %</b>	<b>49.6 %</b>

## Non-GAAP Financial Measures (continued)

- (a) Represents share-based compensation expense to employees and Non-Employee Directors.
- (b) Represents the effects of (i) fluctuations in foreign currency exchange rates, and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion, and (iii) unrealized gains and losses on interest rate derivatives not designated as hedging instruments.
- (c) Represents (i) certain direct and incremental costs related to the acquisitions of Regulatory Compliance Associates Inc. and BioScience Labs and certain related integration efforts as a result of those acquisitions, (ii) the earnings impact of fair value adjustments (excluding those recognized within amortization expense) resulting from the businesses acquired, and (iii) transition services income and non-cash deferred lease income associated with the terms of the divestiture of the Medical Isotopes business in 2018.
- (d) Represents professional fees, exit costs, severance and other payroll costs, and other costs associated with business optimization and cost savings projects relating to the integration of recent acquisitions, operating structure realignment and other process enhancement projects.
- (e) Represents decommissioning costs, professional fees, severance and other payroll costs, and other costs including ongoing lease and utility expenses associated with the closure of the Willowbrook, Illinois facility. The twelve months ended September 30, 2023, June 30, 2023 and March 31, 2023 also includes a \$1.0 million cancellation fee received from a tenant in connection with the termination of an office space lease at the Nordion facility.
- (f) Represents an impairment charge on our equity method investment in a joint venture.
- (g) Represents litigation and other professional fees associated with our EO sterilization facilities. This includes \$18.0 million, \$7.8 million and \$2.3 million of interest expense, net for the twelve months ended September 30, 2023, June 30, 2023 and March 31, 2023, respectively, associated with Term Loan B that was issued to finance the \$408.0 million settlement of approximately 880 pending and threatened EO claims against the Defendant Subsidiaries in Illinois under Settlement Agreements entered into on March 28, 2023.
- (h) Represents the cost to settle approximately 880 pending and threatened EO claims against the Defendant Subsidiaries in Illinois pursuant to Settlement Agreements entered into on March 28, 2023.
- (i) Represents the cost to settle 79 pending EO claims against the Defendant Subsidiaries in Georgia under a Settlement Term Sheet entered into on December 21, 2023.
- (j) Represents non-cash accretion of asset retirement obligations related to gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.
- (k) Represents non-recurring costs associated with the COVID-19 pandemic, including incremental costs to implement workplace health and safety measures.
- (l) Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities, and unusual items from our presentation of adjusted net income.
- (m) The twelve months ended September 30, 2023, June 30, 2023 and March 31, 2023 excludes \$18.0 million, \$7.8 million and \$2.3 million of interest expense, net on Term Loan B attributable to the loan proceeds that were used to fund the \$408.0 million Illinois EO litigation settlement. The twelve months ended September 30, 2023, June 30, 2023, and March 31, 2023 also excludes a \$7.8 million, \$11.1 million, \$8.0 million, respectively, of net decreases in the fair value of interest rate derivatives not designated as hedging instruments recorded to interest expense.
- (n) Includes depreciation of Co-60 held at gamma irradiation sites.
- (o) Represents the difference between income tax expense or benefit as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (l).
- (p) \$90.5 million, \$90.2 million and \$86.7 million of the adjustments for the twelve months ended September 30, 2023, June 30, 2023 and March 31, 2023, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.

## Non-GAAP Financial Measures (continued)

	<u>As of December 31,</u> <u>2022</u>	<u>As of March 31,</u> <u>2023</u>	<u>As of June 30,</u> <u>2023</u>	<u>As of September 30,</u> <u>2023</u>	<u>As of December 31,</u> <u>2023</u>
Current portion of long-term debt	\$ 197,119	\$ 4,031	\$ 5,225	\$ 5,235	\$ 4,797
Long-term debt less current portion	\$ 1,747,115	\$ 2,222,333	\$ 2,221,987	\$ 2,222,789	\$ 2,223,674
Current portion of finance leases	\$ 1,722	\$ 8,588	\$ 8,605	\$ 8,398	\$ 8,771
Finance leases less current portion	\$ 56,955	\$ 61,735	\$ 61,283	\$ 63,219	\$ 63,793
<b>Total Debt</b>	<b>\$ 2,002,911</b>	<b>\$ 2,296,687</b>	<b>\$ 2,297,100</b>	<b>\$ 2,299,641</b>	<b>\$ 2,301,036</b>
Less: cash and cash equivalents	\$ (395,214)	\$ (647,948)	\$ (262,700)	\$ (244,959)	\$ (296,407)
<b>Total Net Debt</b>	<b>\$ 1,607,697</b>	<b>\$ 1,648,739</b>	<b>\$ 2,034,400</b>	<b>\$ 2,054,682</b>	<b>\$ 2,004,628</b>
Adjusted EBITDA <sup>(1)</sup>	\$ 506,249	\$ 489,368	\$ 481,718	\$ 490,894	\$ 528,029
<b>Net Leverage</b>	<b>3.2x</b>	<b>3.4x</b>	<b>4.2x</b>	<b>4.2x</b>	<b>3.8x</b>

(1) Represents Adjusted EBITDA for the twelve months ended September 30, 2023, June 30, 2023, March 31, 2023, and December 31, 2022, respectively. This is a non-GAAP financial measure. Please refer to Non-GAAP Financial Measures provided in the Appendix.

# Non-GAAP Financial Measures Definitions

- **Adjusted Net Income** is defined as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period.
- **Adjusted EBITDA** is defined as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income.
- **Adjusted EBITDA margin** is equal to Adjusted EBITDA divided by net revenues.
- **Segment income margin** is equal to segment income divided by net segment revenues.
- **Adjusted EPS** is defined as Adjusted Net Income divided by the weighted average number of diluted shares outstanding.
- **Net Debt** is equal to our total debt, plus unamortized debt issuance costs and debt discounts, less cash and cash equivalents.
- **Net Leverage Ratio** is equal to Net Debt divided by Adjusted EBITDA
- We calculate **constant currency** net revenues by translating prior year net revenues in local currency at the average exchange rates applicable for the current period. The translated results are then used to determine year-over-year percentage increases or decreases. We generally refer to such amounts calculated on a constant currency basis as excluding the impact of foreign currency exchange rates.